Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
Author:
Gentile MassimoORCID, Morabito Fortunato, Del Poeta Giovanni, Mauro Francesca Romana, Reda Gianluigi, Sportoletti PaoloORCID, Laurenti Luca, Coscia Marta, Herishanu Yair, Recchia Anna Grazia, Varettoni Marzia, Murru Roberta, Chiarenza Annalisa, Condoluci Adalgisa, Moia Riccardo, Pietrasanta Daniela, Loseto Giacomo, Consoli Ugo, Scortechini Ilaria, Rossi Francesca Maria, Zucchetto Antonella, Fraticelli Vincenzo, Vigna Ernesto, Botta CirinoORCID, Tripepi Giovanni, Arrigo Graziella D’, Rago Angela, Angeletti Ilaria, Biagi Annalisa, Del Giudice Ilaria, Bomben Riccardo, Rigolin Gian Matteo, Rossi Davide, Di Raimondo Francesco, Gaidano Gianluca, Polliack Aaron, Cuneo Antonio, Foà Robin, Gattei Valter
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference4 articles.
1. Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, et al. Lancet Haematol. 2019;6:e366–74. 2. Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49–62. 3. Hosmer D, Lemeshow S. Applied logistic regression. 2nd ed. New York, NY: John Wiley & Sons, Inc.; 2000. p. 156–64. 4. Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, et al. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018;103:1209–17.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|